15,071 Shares in GeneDx Holdings Corp. $WGS Acquired by Quantitative Investment Management LLC

Quantitative Investment Management LLC bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS) in the third quarter, Holdings Channel.com reports. The institutional investor bought 15,071 shares of the company’s stock, valued at approximately $1,623,000.

Other large investors also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its stake in shares of GeneDx by 664.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares during the last quarter. Gordian Capital Singapore Pte Ltd bought a new position in shares of GeneDx during the 3rd quarter valued at $65,000. AlphaQuest LLC lifted its stake in shares of GeneDx by 70.8% in the 3rd quarter. AlphaQuest LLC now owns 1,303 shares of the company’s stock valued at $140,000 after purchasing an additional 540 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in GeneDx in the third quarter worth $187,000. Finally, Tower Research Capital LLC TRC boosted its holdings in GeneDx by 479.0% in the second quarter. Tower Research Capital LLC TRC now owns 1,818 shares of the company’s stock worth $168,000 after purchasing an additional 1,504 shares in the last quarter. 61.72% of the stock is owned by institutional investors.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $76.85 on Friday. The company has a market cap of $2.25 billion, a price-to-earnings ratio of -102.47 and a beta of 2.03. The business has a 50 day moving average price of $97.36 and a 200 day moving average price of $121.15. The company has a quick ratio of 2.34, a current ratio of 2.46 and a debt-to-equity ratio of 0.16. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $170.87.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The company had revenue of $120.99 million during the quarter, compared to analyst estimates of $120.80 million. Research analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

WGS has been the topic of several analyst reports. Wells Fargo & Company raised shares of GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price on the stock in a research report on Monday, February 9th. Piper Sandler reiterated an “overweight” rating and set a $130.00 price target (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Zacks Research raised GeneDx from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 25th. Canaccord Genuity Group raised their price objective on GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Finally, Jefferies Financial Group set a $150.00 target price on GeneDx in a research report on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, GeneDx has a consensus rating of “Moderate Buy” and a consensus target price of $150.71.

Insider Activity at GeneDx

In other news, CFO Kevin Feeley sold 6,187 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $78.61, for a total transaction of $486,360.07. Following the transaction, the chief financial officer owned 18,674 shares in the company, valued at approximately $1,467,963.14. The trade was a 24.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Keith A. Meister bought 140,026 shares of GeneDx stock in a transaction that occurred on Thursday, March 5th. The stock was bought at an average price of $81.19 per share, with a total value of $11,368,710.94. Following the purchase, the director owned 3,228,150 shares of the company’s stock, valued at $262,093,498.50. This trade represents a 4.53% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 57,702 shares of company stock valued at $5,640,255 in the last 90 days. 29.60% of the stock is owned by company insiders.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.